Dive deeper
Open any topic for the full explanation, tables, clinical checkpoints, and references.
Full-length video Where can I learn more about basal cell carcinoma?
What does a basal cell carcinoma diagnosis mean?
What Does a Basal Cell Carcinoma Diagnosis Mean?
Your epidermis is the outer layer of skin. Its deepest row contains basal keratinocytes, and related cells also sit around hair follicles. Under the microscope, BCC cells resemble these basal-type cells. That is where the name comes from.1,5
The word carcinoma means a malignant tumor arising from epithelial cells. “Malignant” does not mean that every BCC behaves the same way. It means the cells can continue growing, invade nearby tissue, and return if tumor remains. The rest of the pathology report helps estimate how predictable that growth is.
BCC is not melanoma
Melanoma begins in melanocytes, the cells that make pigment. BCC begins in a keratinocyte lineage. A pigmented BCC may look brown or black because pigment is present around the tumor, but that does not make it melanoma. Likewise, an untreated BCC does not evolve into melanoma. A person can develop both cancers separately, which is one reason the exact biopsy diagnosis matters.1,6
A realistic example
Two people can both hear “basal cell carcinoma” and still need different plans. One has a first, sharply defined nodular BCC on the upper back. The other has a recurrent infiltrative BCC beside the nostril. The diagnosis is the same; the anatomy, growth pattern, recurrence history, and consequences of residual tumor are not.
How common is basal cell carcinoma?
How Common Is BCC?
BCC is widely described as the most common human cancer, but the United States does not have a complete current national count. Ordinary BCC of the skin is not routinely reportable to the Surveillance, Epidemiology, and End Results program, so national cancer-registry tables do not supply the denominator that exists for melanoma and many internal cancers.2
Evidence by the NumbersCommon, but incompletely counted
Common, but incompletely counted
226.09 incident patients per 100,000 insured people during the one-year study period
- Population
- Commercially insured U.S. adults meeting a claims algorithm for BCC
- Denominator
- The continuously insured MarketScan population; 56,987 identified patients, including 39,035 classified incident cases
- Comparator
- No clinical comparator
- Outcome
- Age-adjusted incident patients per 100,000 insured people
- Time horizon
- October 1, 2011 through September 30, 2012
What it means: BCC is common, but registry and claims limitations prevent one precise current U.S. count.
Limitations: Not a current national population rate; algorithmic claims, commercially insured adults, and patients rather than every separate tumor
What causes BCC and which risk factors matter?
What Causes BCC, and Which Risk Factors Matter?
The main preventable cause is ultraviolet radiation from sunlight and indoor tanning. UV injury accumulates and can also come in intense episodes. DNA-repair and growth-control pathways then fail in a cell that begins to reproduce without normal limits.1,4,5
Risk rises with several kinds of exposure or susceptibility:
- substantial lifetime sun exposure, blistering sunburns, or indoor tanning;
- skin that burns easily, light eyes, or naturally light or red hair - while remembering that BCC occurs in every skin tone;
- increasing age, because damage has had more time to accumulate;
- a previous BCC or another keratinocyte cancer;
- immune suppression, including after organ transplantation or from some medications or illnesses;
- prior therapeutic radiation to the area;
- arsenic exposure; and
- uncommon inherited syndromes that predispose to multiple early BCCs.1,4,5
These factors do not diagnose an individual spot. Someone with darker skin or little remembered sunburn can still develop BCC. Someone with many risk factors can still have a benign bump. Risk changes how closely a finding deserves evaluation; pathology establishes the tissue diagnosis when needed.
What does the BCC pathology name mean?
What Does the Pathology Name Mean?
A pathology report often gives more than the word BCC. These terms describe the portion sampled:
| Pathology term | Plain-language meaning | Why it can matter |
|---|---|---|
| Nodular | Rounded nests of tumor cells | Often a more predictable pattern when other features are lower risk |
| Superficial | Tumor growing in shallow connections along the epidermis | Selected lower-risk sites may qualify for nonsurgical options |
| Infiltrative or morpheaform/sclerosing | Narrow strands extend through firm tissue and may reach beyond the visible edge | Often raises the value of complete mapped margin assessment |
| Micronodular | Small deeper nests can extend beyond an obvious surface boundary | Treated as a more aggressive growth pattern |
| Basosquamous differentiation | Areas show both basal and squamous differentiation | Usually prompts a higher-risk discussion rather than routine low-risk assumptions |
| Perineural involvement | Tumor is seen around or within a nerve | Can change risk, imaging, treatment, and follow-up, especially when clinically significant |
| Pigmented | Melanin is present in or around the tumor | Describes color; it does not mean melanoma |
A biopsy is a sample, not a clearance certificate
Biopsy is the reference standard when a tissue diagnosis is needed, but it samples a portion of a three-dimensional lesion. In a selected Mohs series, 28% of BCCs called nonaggressive on biopsy contained an aggressive component when more tumor was examined. That finding does not mean every apparently lower-risk BCC needs Mohs; it means the biopsy, clinical border, site, and consequences of under-sampling must be considered together.8
Evidence by the NumbersA negative biopsy edge is not a clearance certificate
A negative biopsy edge is not a clearance certificate
50 of 182 BCCs, or 27.5%, had residual tumor
- Population
- Biopsy-proven BCC diagnostic-biopsy specimens, predominantly shave biopsies, with negative-reported histologic margins that underwent additional treatment in four observational studies
- Denominator
- 182 BCCs
- Comparator
- No direct treatment comparator; residual tumor was assessed at further treatment
- Outcome
- Residual BCC found in the definitive specimen
- Time horizon
- At subsequent definitive treatment
What it means: No tumor at the examined biopsy edge does not prove the entire lesion was removed.
Limitations: Selected negative-margin diagnostic-biopsy cohorts; the pooled studies were predominantly, but not exclusively, shave-biopsy cohorts and do not predict every biopsy technique or procedure
References: 9
What can basal cell carcinoma look like?
What Can BCC Look Like?
BCC has several visual patterns. One photograph cannot show its full history, texture, depth, or microscopic subtype, and it cannot reliably separate BCC from every benign growth, squamous cell carcinoma, or melanoma.5,6
| Possible BCC appearance | Commonly noticed features | Examples that can look similar | Safe interpretation |
|---|---|---|---|
| Pearly or translucent bump | Shiny surface, tiny visible blood vessels, rolled edge | Benign mole, sebaceous hyperplasia, fibrous papule, cyst | A classic clue, not a diagnosis |
| Sore that repeatedly crusts, bleeds, or does not heal | Ulcer, scab that returns, easy bleeding | Trauma, dermatitis, infection, squamous cell carcinoma | Persistence or recurrence deserves examination |
| Scaly pink or red patch | Thin plaque that can resemble dry skin | Eczema, psoriasis, actinic keratosis, superficial squamous lesion | Superficial BCC can be subtle; response to moisturizer does not establish the diagnosis |
| Firm scar-like area | White, yellow, pink, waxy, or bound-down surface with an indistinct edge | Scar, morphea, other infiltrative tumors | A new “scar” without an injury deserves attention |
| Brown, blue-gray, or black lesion | Pigment within a bump, patch, or ulcer | Benign mole, seborrheic keratosis, melanoma | Pigment does not make a BCC melanoma, but a dark lesion still needs proper evaluation |
Pigmentation may be especially prominent in BCCs in darker skin tones. A pearl-pink-only checklist therefore misses real presentations. The useful home observation is change: a spot that persists, grows, bleeds, ulcerates, or looks unlike the surrounding skin deserves a clinician's assessment.5,6
Memorable rule: a photograph can raise a question; it cannot close the case.
How does BCC grow, spread, and affect survival?
How Does BCC Grow, Spread, and Affect Survival?
BCC usually causes trouble by growing where it began. It can follow microscopic paths beyond the visible border and, if allowed to enlarge, can ulcerate or invade fat, muscle, cartilage, bone, or nerves. Tumors near the eye, nose, lip, ear, or another functionally important structure can cause disproportionate harm even without distant spread.1,7
Evidence by the NumbersDistant spread is rare, not impossible
Distant spread is rare, not impossible
Approximately 0.003% to 0.55%, or about 3 to 550 per 100,000 diagnosed BCCs
- Population
- Diagnosed BCCs represented across heterogeneous published reviews
- Denominator
- 100,000 diagnosed BCCs used for absolute translation
- Comparator
- No direct comparator
- Outcome
- Reported metastatic BCC
- Time horizon
- Variable follow-up across the literature
What it means: Most BCCs do not spread through the body, but rare is not never and local invasion still matters.
Limitations: Wide, imprecise range; reported cases cluster in unusually large, neglected, recurrent, or aggressive tumors
References: 1
What about death from BCC?
A trustworthy current U.S. BCC-specific annual death count or population mortality rate is not available from SEER because routine skin BCC is not reportable to that registry. Combined “nonmelanoma skin cancer” death totals mix diseases with different behavior and should not be relabeled as BCC deaths. The missing number is a measurement limitation, not proof of zero deaths.2
For a person with a routine localized BCC, published metastatic-case survival statistics are not the right comparison. If a tumor is locally advanced or metastatic, prognosis belongs to a specialist discussion using the person's extent of disease, prior treatment, and current systemic options.
Memorable rule: BCC usually grows outward and inward before it goes elsewhere.
What can happen if BCC is untreated?
What Can Happen If BCC Is Untreated?
Untreated BCC can remain small for a time, grow slowly, or enlarge more quickly. It may bleed, ulcerate, become painful, invade a nearby structure, and require a larger operation and repair. The surface can look quiet while microscopic strands continue beyond it. Waiting also gives an aggressive or under-sampled component more time to declare itself.1,7,10,11
Observation is sometimes a deliberate medical choice for an older or frail person whose tumor appears lower risk and whose competing health problems or treatment burden outweigh the likely benefit of immediate treatment. That is different from losing the diagnosis to follow-up.
Evidence by the NumbersSelected observation is not a general safety rule
Selected observation is not a general safety rule
58 of 124 repeatedly measured tumors (46.8%) grew; estimated growth was 4.46 mm/year for infiltrative or micronodular tumors and 1.06 mm/year for other subtypes
- Population
- Mostly older patients selected for watchful waiting; median age 83 years
- Denominator
- 89 patients with 280 BCCs; 124 tumors had repeated measurements for the reported growth analysis
- Comparator
- Infiltrative or micronodular tumors versus other BCC subtypes
- Outcome
- Tumor growth and estimated annual diameter growth
- Time horizon
- Median follow-up 9 months
What it means: Observation may fit a documented frailty or life-expectancy decision, but it does not show that routine delay is safe.
Limitations: Selected older patients, short follow-up, and incomplete repeated measurement; not a general untreated-BCC natural-history rate
References: 10
Which BCCs are lower risk or higher risk?
Which BCCs Are Lower Risk or Higher Risk?
Risk is a decision tool, not a moral label and not a statement that one patient “caused” a worse tumor. A single meaningful high-risk feature can change the treatment pathway; several aligned features should not be averaged away.7
| Decision feature | Often supports a lower-risk pathway | Often supports a higher-risk pathway |
|---|---|---|
| Status | First primary tumor | Recurrent, persistent, or previously incompletely treated tumor |
| Location | Suitable trunk or non-pretibial extremity site, when size, borders, and other features fit | Head or neck; hand, foot, pretibial, or anogenital site. Under current U.S. guidelines, these locations count as higher risk at any size. Central face, eyelid, nose, lip, and ear are especially tissue-sensitive |
| Clinical border | Sharply defined | Poorly defined or scar-like |
| Size and depth | Small and superficial for its site | Larger for its site, deeply invasive, or involving cartilage, bone, or another structure |
| Pathology | Nodular or superficial pattern without another adverse feature | Infiltrative, morpheaform/sclerosing, micronodular, basosquamous differentiation, or other aggressive pattern |
| Nerves | No perineural involvement identified | Perineural involvement, especially with pain, numbness, weakness, or a named nerve |
| Patient and field | No major immune suppression; no prior radiation to the site | Immune suppression, prior radiation, or a genetic syndrome that changes tumor behavior |
These columns are not a self-scoring checklist. Guideline size thresholds depend on anatomic zone, a biopsy can under-sample a mixed tumor, and patient health can appropriately change the balance between treatment reliability and burden.7,8
Two examples
Lower-risk example: a first, small, sharply defined nodular BCC on a suitable trunk site in a person without immune suppression may fit standard excision or another selected treatment.
Higher-risk example: a recurrent, poorly defined infiltrative BCC on the nose combines recurrence, aggressive microscopic growth, and tissue-sensitive anatomy. That combination earns a serious discussion of Mohs or another form of complete peripheral and deep margin assessment.7,12
How is basal cell carcinoma diagnosed?
How Is BCC Diagnosed?
Diagnosis starts with history and examination: how long the spot has been present, whether it changes or bleeds, what it feels like, its borders, dermoscopic features, the surrounding skin, and the patient's other lesions and risk factors. A photograph is one input, not the whole assessment.5,6
When confirmation is needed, the clinician takes a biopsy. A shave, punch, or excisional sample is selected to answer the diagnostic question while considering site, suspected depth, bleeding risk, and the future treatment plan. A dermatopathologist examines the tissue and reports the diagnosis and sampled growth pattern.5,8
After the result, the clinician should reconcile three maps:
- The clinical map: location, size, visible border, symptoms, recurrence, and prior treatment.
- The pathology map: subtype, depth represented, nerve involvement, and what the sample can or cannot show.
- The patient map: immune status, medications, health, preferences, and the functional cost of recurrence or treatment.
If those maps disagree - for example, a superficial biopsy from a firm, scar-like lesion on the nose - the answer is not to ignore one of them. The discrepancy deserves review before choosing a treatment that assumes the biopsy captured the entire risk pattern.7,8
How urgent is BCC treatment and what happens next?
How Urgent Is Treatment, and What Happens Next?
Most localized BCCs do not require an emergency department visit. They do require a real plan. Urgency rises with faster growth, symptoms, aggressive pathology, recurrence, critical anatomy, immune suppression, and signs of local or distant spread.7,11
| Situation | Reasonable urgency | High-level next step |
|---|---|---|
| Possible BCC, not yet biopsied | Arrange clinical assessment; accelerate if it is rapidly growing, repeatedly bleeding, painful, or near a critical structure | Examination and biopsy when tissue diagnosis is needed |
| Biopsy-proven, apparently lower-risk localized BCC | Usually a planned outpatient timeline rather than an emergency; do not leave it indefinitely | Confirm risk and discuss standard excision or another properly selected local option |
| Recurrent, ill-defined, aggressive-subtype, or tissue-sensitive BCC | Prompt treatment planning because delay can enlarge the cancer and repair problem | Discuss Mohs or another complete-margin strategy; coordinate reconstruction when needed |
| Pain, numbness, weakness, eye/ear dysfunction, rapid destruction, or immune suppression | Contact the treating team promptly; these features can change workup and timing | Re-examination, pathology review, and selective imaging or specialist input |
| Locally advanced, nodal, or metastatic BCC | Urgent multidisciplinary evaluation | Dermatologic surgery, head and neck or surgical oncology, radiation oncology, and medical oncology as appropriate |
Treatment in one paragraph
Standard excision is an excellent choice for many primary, well-defined lower-risk BCCs. Curettage and electrodesiccation can fit selected lower-risk BCCs. Topical therapies fit selected low-risk superficial BCCs. Photodynamic therapy can also fit selected superficial BCCs; under current U.S. guidance, it is a nonsurgical option for tumors clinically and histologically consistent with superficial BCC without dermal extension, and it should not inherit the indications of surgery for high-risk, recurrent, aggressive, or ill-defined tumors. Radiation can be appropriate when surgery is infeasible or declined and in selected adjunctive settings. Mohs or another complete peripheral and deep margin assessment is often preferred when recurrence, aggressive histology, ill-defined borders, high-risk anatomy, or tissue preservation makes residual tumor especially consequential. Locally advanced or metastatic BCC may require targeted therapy or immunotherapy through a multidisciplinary team.7,12–14
For treatment details, continue to Basal Cell Carcinoma Treatment Options. If you are comparing pathways, see Low-Risk vs High-Risk Skin Cancer, Do I Need Mohs Surgery?, When Simpler Skin Cancer Treatments Fit, and How Urgent Is Skin Cancer Treatment?.
What is the prognosis after BCC treatment?
What Is the Prognosis?
For most localized BCCs, prognosis after appropriate treatment is excellent. “Excellent” should not be translated into “nothing matters.” Recurrence risk depends on the original tumor, the treatment and margin method, the site, immune status, and how long follow-up continues. A high-risk recurrent facial BCC should not borrow a cure statistic from a first small superficial trunk tumor.7,12
After one BCC, ongoing skin surveillance matters because the same susceptibility that produced the first tumor can produce another separate skin cancer. A new BCC elsewhere is usually a new primary, not spread from the first. Follow-up should include the treated site, the rest of the skin, sun protection, and a clear call-sooner plan.1,7
What should I ask at the next BCC visit?
Questions to Ask at the Next Visit
- What is the exact pathology subtype, and could this biopsy have sampled only part of a mixed tumor?
- Is this BCC lower risk or higher risk, and which specific feature places it there?
- Does the biopsy margin language describe only the sample, or was the procedure intended as definitive removal?
- What treatment gives enough margin confidence for this site and tumor?
- If Mohs is recommended, which anatomy, recurrence, border, or pathology feature makes it valuable here?
- If a simpler treatment is recommended, what makes this tumor an appropriate candidate and how will response be followed?
- How soon should treatment occur, and what change should make me call sooner?
- What follow-up schedule fits my tumor and my history after treatment?
Frequently asked questions about basal cell carcinoma
Frequently Asked Questions
Is BCC harmless?
No. Most BCCs are highly treatable and rarely spread distantly, but they can invade and destroy nearby tissue, recur, and occasionally become locally advanced or metastatic. “Usually manageable” is accurate; “harmless” is not.1,7
Does BCC turn into melanoma?
No. They arise from different cell lineages. A person can develop both as separate cancers, and a pigmented BCC can visually mimic melanoma, but BCC does not transform into melanoma.1,6
Can a biopsy remove the whole BCC?
Sometimes the visible lesion may be physically removed by the biopsy, especially when it is small. You cannot prove complete treatment from appearance or a negative biopsy edge alone. The biopsy method, pathology, remaining clinical lesion, site, and treatment intent determine the next step.9
Does every BCC need Mohs surgery?
No. Many well-defined primary lower-risk BCCs are appropriately treated with standard excision or another selected option. Mohs becomes especially valuable when complete mapped margins and tissue preservation can change care, including recurrent, aggressive, ill-defined, or high-risk-site tumors.7,12
How fast does BCC grow?
There is no safe universal rate. In one selected older watchful-waiting cohort, repeatedly measured infiltrative or micronodular tumors grew faster on average than other subtypes, but individual tumors varied and follow-up was short. Do not use an average growth rate as permission to delay your own plan.10
Can BCC occur in darker skin?
Yes. It is less common in some more deeply pigmented populations, but it occurs in every skin tone and may be more visibly pigmented. A dark BCC can be mistaken for a benign growth or melanoma, which is why examination and biopsy matter.6
Should I go to an emergency department?
Most localized BCCs are handled through planned outpatient care. Contact the treating team promptly for rapid enlargement, uncontrolled bleeding, severe pain, numbness, weakness, eye or ear symptoms, a large destructive tumor, immune suppression, or concern for spread.7
Where should I go next in the Patient Journey?
Next Steps in the Patient Journey
Continue with the question that best fits what you know now. Your dermatologist or treating team can apply the complete pathology and examination to your situation.
Continue with the question that fits you now
Who reviewed and authored this BCC guide?
References for this basal cell carcinoma guide
References
- Rubin AI, Chen EH, Ratner D. Basal-cell carcinoma. New England Journal of Medicine. 2005;353(21):2262-2269. PMID: 16306523. doi:10.1056/NEJMra044151.
- National Cancer Institute, Surveillance, Epidemiology, and End Results Program. SEER Program Coding and Staging Manual 2025: Reportability. 2025. https://seer.cancer.gov/manuals/2025/SPCSM_2025_MainDoc.pdf
- Goldenberg G, Karagiannis T, Palmer JB, et al. Incidence and prevalence of basal cell carcinoma and locally advanced basal cell carcinoma in a large commercially insured population in the United States: a retrospective cohort study. Journal of the American Academy of Dermatology. 2016;75(5):957-966.e2. PMID: 27473450. doi:10.1016/j.jaad.2016.06.020.
- Wu S, Han J, Li WQ, Li T, Qureshi AA. Basal-cell carcinoma incidence and associated risk factors in U.S. women and men. American Journal of Epidemiology. 2013. PMID: 23828250; PMCID: PMC3775544.
- Marzuka AG, Book SE. Basal cell carcinoma: pathogenesis, epidemiology, clinical features, diagnosis, histopathology, and management. Yale Journal of Biology and Medicine. 2015;88(2):167-179. PMID: 26029015; PMCID: PMC4445438.
- Karampinis E, Aloizou AM, Houssein E, et al. Basal cell carcinoma in skin of color: diagnostic and management considerations. Medicina. 2024. PMID: 39336428; PMCID: PMC11434363.
- National Comprehensive Cancer Network. Basal Cell Skin Cancer. Version 2.2026.
- Moon D, Randall G, Higgins S, Sutton AV, Wysong A. Misclassification of aggressive basal cell carcinoma subtypes and implications for management. Dermatologic Surgery. 2021. PMID: 33905389.
- Purnell JC, Duncan JR, Stratton MS, Huang C, Phillips CB. Negative predictive value of biopsy margins in keratinocyte carcinoma. Dermatologic Surgery. 2020. PMID: 31567613. doi:10.1097/DSS.0000000000002171.
- van Winden MEC, Hetterschijt CR, Bronkhorst EM, et al. Evaluation of watchful waiting and tumor behavior in patients with basal cell carcinoma. JAMA Dermatology. 2021. PMID: 34495284. doi:10.1001/jamadermatol.2021.3020.
- Eide MJ, Weinstock MA, Dufresne RG Jr, et al. Relationship of treatment delay with surgical defect size from keratinocyte carcinoma. Journal of Investigative Dermatology. 2005. PMID: 15675948.
- van Loo E, Mosterd K, Krekels GA, et al. Surgical excision versus Mohs micrographic surgery for basal cell carcinoma of the face: a randomized clinical trial with 10-year follow-up. European Journal of Cancer. 2014. PMID: 25262378. doi:10.1016/j.ejca.2014.08.018.
- Likhacheva A, Awan M, Barker CA, et al. Definitive and postoperative radiation therapy for basal and squamous cell cancers of the skin: executive summary of an ASTRO clinical practice guideline. Practical Radiation Oncology. 2020;10(1):8-20. PMID: 31831330. doi:10.1016/j.prro.2019.10.014.
- Peris K, Fargnoli MC, Kaufmann R, et al. European consensus-based interdisciplinary guideline for diagnosis and treatment of basal cell carcinoma—update 2023. European Journal of Cancer. 2023;192:113254. PMID: 37604067. doi:10.1016/j.ejca.2023.113254. --- This educational article explains evidence and questions to discuss with a qualified clinician. It does not diagnose a lesion from a photograph or replace care from a clinician who can examine the site and review the pathology.